{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:56:37Z","timestamp":1786949797609,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>From January 1970 to December 2018, 1304 patients were diagnosed with multiple myeloma (MM) at our institution and 256 (19.6%) had plasmacytomas (Ps) (paraskeletal \u2013PPs- 17.6%, extramedullary \u2013EMPs-1.9%). Patients with Ps had lower serum M-protein and less advanced ISS stage than those without. At first relapse, 192 out of 967 patients (19.8%) developed Ps (PPs 14.6%, EMPs 5.1%). The only factor associated with Ps at relapse was the presence of Ps at diagnosis (46% vs 13%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001) with no impact with exposure to novel drugs or previous autologous stem-cell transplantation (ASCT). The median overall survival (OS) was 45, 44 and 20\u2009months for patients without Ps, PPs and EMPs, respectively (<jats:italic>p<\/jats:italic>\u2009=\u20090.013). Patients with PPs who underwent ASCT had similar OS than those without Ps (98 vs. 113\u2009months) and significantly longer than those with EMPs (98 vs 47\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.006). In patients non-eligible for ASCT the presence of PPs or EMPs was associated with shorter OS compared with patients without Ps (32 vs. 24 vs. 6\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.009). In the relapsed setting, a significant survival benefit was observed beyond the year 2000, but still with significant differences among patients without Ps, PPs and EMPs (37 vs 22 vs 16\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.003). Importantly, rescue therapy with combinations of proteasome-inhibitors plus immunomodulatory drugs was associated with prolonged OS from first relapse (over 6\u2009years), even in patients with EMPs.<\/jats:p>","DOI":"10.1038\/s41408-022-00730-5","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T04:06:54Z","timestamp":1663301214000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution"],"prefix":"10.1038","volume":"12","author":[{"given":"Raquel","family":"Jim\u00e9nez-Segura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Teresa","family":"Cibeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-0921","authenticated-orcid":false,"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-5420","authenticated-orcid":false,"given":"Aina","family":"Oliver-Cald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-3405","authenticated-orcid":false,"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"730_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","volume":"93","author":"J Blad\u00e9","year":"1996","unstructured":"Blad\u00e9 J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40\u2009years. Br J Haematol. 1996;93:345\u201351.","journal-title":"Br J Haematol"},{"key":"730_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325\u201330.","journal-title":"Ann Oncol"},{"key":"730_CR3","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","volume":"29","author":"J Blad\u00e9","year":"2011","unstructured":"Blad\u00e9 J, Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, Cibeira MT, Jim\u00e9nez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread and treatment approach. J Clin Oncol. 2011;29:3805\u201312.","journal-title":"J Clin Oncol"},{"key":"730_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Buthani","year":"2020","unstructured":"Buthani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1\u201320.","journal-title":"Leukemia"},{"key":"730_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194:496\u2013507.","journal-title":"Br J Haematol"},{"key":"730_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1600-0609.2010.01504.x","volume":"85","author":"C Fern\u00e1ndez de Larrea","year":"2010","unstructured":"Fern\u00e1ndez de Larrea C, Rosi\u00f1ol L, Cibeira MT, Rozman M, Rovira M, Blad\u00e9 J. Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. Eur J Haematol. 2010;85:448\u201351.","journal-title":"Eur J Haematol"},{"key":"730_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000354830","volume":"132","author":"E Muchtar","year":"2014","unstructured":"Muchtar E, Raanani P, Yeshurun M, Shpilberg O, Magen-Nativ H. Myeloma in scar tissue- an underreported phenomenon or an emerging entity in the novel agents\u2019 era? A single center series. Acta Haematol. 2014;132:39\u201344.","journal-title":"Acta Haematol"},{"key":"730_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.26502\/acbr.50170142","volume":"4","author":"DF Moreno","year":"2020","unstructured":"Moreno DF, Setoain X, Blad\u00e9 J, Rosi\u00f1ol L. Extramedullary plasmacytoma over the scar from long-lasting past surgery as presenting feature of multiple myeloma. Arch Clin Biomed Res. 2020;4:766\u201374.","journal-title":"Arch Clin Biomed Res"},{"key":"730_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1080\/10428190802657751","volume":"50","author":"P Wu","year":"2009","unstructured":"Wu P, Davies FE, Boyd K, Thomas K, Dines S, Saso RM, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50:230\u20135.","journal-title":"Leuk Lymphoma"},{"key":"730_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00277-014-2216-8","volume":"94","author":"SE Lee","year":"2015","unstructured":"Lee SE, Kim JH, Jeon YW, Yoon JH, Shin SH, Eom KS, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015;94:445\u201352.","journal-title":"Ann Hematol"},{"key":"730_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3324\/haematol.2017.178434","volume":"103","author":"N Gagelmann","year":"2018","unstructured":"Gagelmann N, Eikema DJ, Iacobelly S, Koster L, Nahi H, Stoppa AM, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103:890\u20137.","journal-title":"Haematologica"},{"key":"730_CR12","doi-asserted-by":"publisher","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022. https:\/\/doi.org\/10.1038\/s41408-022-00643-3.","DOI":"10.1038\/s41408-022-00643-3"},{"key":"730_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761\u20137.","journal-title":"Haematologica"},{"key":"730_CR14","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013346.","journal-title":"Lancet Oncol"},{"key":"730_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.78","volume":"7","author":"J Hillengass","year":"2017","unstructured":"Hillengass J, Moulopoulos LA, Delorme S, Koutulidis V, Mosebach J, Hielscher T, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 2017;7:e599. https:\/\/doi.org\/10.1038\/bcj.2017.78","journal-title":"Blood Cancer J"},{"key":"730_CR16","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cells disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206\u2013e217.","journal-title":"Lancet Oncol"},{"key":"730_CR17","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","volume":"20","author":"J Hillengass","year":"2019","unstructured":"Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302\u2013312.","journal-title":"Lancet Oncol"},{"key":"730_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.13383","volume":"169","author":"M Weinstock","year":"2015","unstructured":"Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169:851\u20138.","journal-title":"Br J Haematol"},{"key":"730_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, Kupsta R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360\u20134.","journal-title":"Haematologica"},{"key":"730_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjh.13382","volume":"169","author":"C Varga","year":"2015","unstructured":"Varga C, Xie W, Laubach J, Ghobrial IM, O\u2019Donnell EK, Weinstock M, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169:843\u201350.","journal-title":"Br J Haematol"},{"key":"730_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2019.219139","volume":"105","author":"V Montefusco","year":"2020","unstructured":"Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, et al. Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica. 2020;105:193\u2013200.","journal-title":"Haematologica"},{"key":"730_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ajh.25579","volume":"94","author":"I Avivi","year":"2019","unstructured":"Avivi I, Cohen YC, Suska A, Sharagai T, Mikala G, Garderet L, et al. Hematogenous extramedullary relapse in multiple myeloma-a multicenter retrospective study in 127 patients. Am J Hematol. 2019;94:1132\u201340.","journal-title":"Am J Hematol"},{"key":"730_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","volume":"91","author":"L Rasche","year":"2012","unstructured":"Rasche L, Bernard C, Topp MS, Kapp M, Duell J, Wesemeier C, et al. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: A retrospective single-center study of 24 cases. Ann Hematol. 2012;91:1031\u20137.","journal-title":"Ann Hematol"},{"key":"730_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clml.2014.12.013","volume":"15","author":"S Deng","year":"2015","unstructured":"Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15:286\u201391.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"730_CR25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.leukres.2009.01.010","volume":"33","author":"N Sheth","year":"2009","unstructured":"Sheth N, Yeung J, Chang H. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res. 2009;33:1357\u201360.","journal-title":"Leuk Res"},{"key":"730_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1600-0609.2009.01399.x","volume":"84","author":"L L\u00f3pez-Anglada","year":"2010","unstructured":"L\u00f3pez-Anglada L, Guti\u00e9rrez NC, Garc\u00eda JL, Mateos MV, Flores T, San Miguel JF. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol. 2010;84:359\u201361.","journal-title":"Eur J Haematol"},{"key":"730_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.12223","volume":"161","author":"L Billecke","year":"2013","unstructured":"Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161:87\u201394.","journal-title":"Br J Haematol"},{"key":"730_CR28","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","volume":"12","author":"L Rosi\u00f1ol","year":"2012","unstructured":"Rosi\u00f1ol L, Oriol A, Teruel AI, Hern\u00e1ndez D, L\u00f3pez-Jim\u00e9nez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide and dexamethasone (VTD) as induction pre-transplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood. 2012;12:1589\u201396.","journal-title":"Blood"},{"key":"730_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N, Coriu D, Rosi\u00f1ol L, Ozet G, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020;105:201\u20138.","journal-title":"Haematologica"},{"key":"730_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","volume":"96","author":"S Mangiacavalli","year":"2017","unstructured":"Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96:73\u201380.","journal-title":"Ann Hematol"},{"key":"730_CR31","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","volume":"7","author":"SZ Usmani","year":"2020","unstructured":"Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trial. Lancet Haematol. 2020;7:e447\u2013e455.","journal-title":"Lancet Haematol"},{"key":"730_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.clml.2022.04.014","volume":"22","author":"DF Moreno","year":"2022","unstructured":"Moreno DF, Clap\u00e9s V, Soler JA, Gonz\u00e1lez-Montes Y, Gironella M, Motll\u00f3 C, et al. Real-world evidence of daratumumab monotherapy in relapsed\/refractory multiple myeloma patients and efficacy on soft-tissue plasmacytomas. Clin Lymphoma Myeloma Leuk. 2022;22:635\u201342.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"730_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple class refractory multiple myeloma. N. Engl J Med. 2019;381:727\u201338.","journal-title":"N. Engl J Med"},{"key":"730_CR34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Oriol A, Larocca A, Blad\u00e9 J, Cavo M, Rodr\u00edguez-Otero P, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39:757\u201367.","journal-title":"J Clin Oncol"},{"key":"730_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207\u201321.","journal-title":"Lancet Oncol"},{"key":"730_CR36","doi-asserted-by":"publisher","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022 https:\/\/doi.org\/10.1056\/NEJMoa2203478.","DOI":"10.1056\/NEJMoa2203478"},{"key":"730_CR37","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl J Med. 2019;380:1726\u201337.","journal-title":"N. Engl J Med"},{"key":"730_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705\u201316.","journal-title":"N. Engl J Med"},{"key":"730_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-140243","volume":"136","author":"B Wang","year":"2020","unstructured":"Wang B, Liu J, Zhao WH, Chen YX, Cao XM, Yang Y, et al. Chimeric antigen receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease-a single institution observation in China. Blood. 2020;136:6. Suppl 1","journal-title":"Blood"},{"key":"730_CR40","first-page":"700571","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al. Efficacy of humanized antiBCMA CAR T Cell theray in relapsed\/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol. 2021;12:700571.","journal-title":"Front Immunol"},{"key":"730_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1200\/JCO.20.00386","volume":"39","author":"E Zamagni","year":"2021","unstructured":"Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of (18)F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116\u201325.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00730-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00730-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00730-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T04:06:59Z","timestamp":1663301219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00730-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00730-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"24 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LR received honoraria for lectures and advisory boards from Janssen, Celgene\/BMS, Amgen, Takeda, GSK and Sanofi. MTC received honoraria for lectures and advisory boards from Janssen, Amgen and Akcea. CFdL received honoraria for lectures from Janssen, Celgene\/BMS, Amgen, Pfizer, GSK, and Sanofi and research funding from Janssen, Celgene\/BMD, Amgen and Takeda. LGRL received honoraria for lectures from Janssen and Amgen. JB received honoraria for lectures from Janssen, Celgene\/BMS, Amgen, Takeda, Oncopeptides. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}